Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva Hits Pause On Business Development, Even As Some Deals Stumble

Nov 15 2016

• By Jessica Merrill

Hands writing on a paper

Related Content

Teva Adds Needed Latin American Puzzle Piece With Rimsa Buy

Oct 02 2015

Teva Plugs Gap With Celltrion Deal For Rituxan And Herceptin Biosimilar Candidates

Oct 06 2016

Regeneron’s Fasinumab Brings Second Clinical Hold For Anti-NGF Class

Oct 17 2016

Meet The New Teva: 8% Global Generics Share, 300 ANDAs, 1,500 Launches

Sep 15 2016

Related Companies

Teva Pharmaceutical Industries Ltd.

Allergan plc

Celltrion, Inc.

Roche Holding AG

Regeneron Pharmaceuticals, Inc.

NuPathe, Inc.

Additional Topics

Deals Legal Issues Commercial BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window